Evolution of costs of inflammatory bowel disease over two years of follow-up

PLoS ONE

Volumn 11, Issue 4, 2016, Pages

  Van Der Valk, Mirthe E ^a   Mangen, Marie Josée J ^a   Severs, Mirjam ^a   Van Der Have, Mike ^a   Dijkstra, Gerard ^b   Van Bodegraven, Ad A ^c,d   Fidder, Herma H ^a   De Jong, Dirk J ^e   Van Der Woude, C Janneke ^f   Romberg Camps, Mariëlle J L ^d   Clemens, Cees H M ^g   Jansen, Jeroen M ^h   Van De Meeberg, Paul C ⁱ   Mahmmod, Nofel ^j   Van Der Meulen De Jong, Andrea E ^k   Ponsioen, Cyriel Y ^l   Bolwerk, Clemens ^m   Vermeijden, J Reinoud ⁿ   Siersema, Peter D ^a   Leenders, Max ^a   Oldenburg, Bas ^a   more..

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d Zuyderland Medical Centre   (Netherlands)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f ERASMUS MEDICAL CENTER   (Netherlands)

^g Diaconessenhuis ^*  (Netherlands)

^h ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

ⁱ SLINGELAND HOSPITAL   (Netherlands)

^j ST ANTONIUS HOSPITAL   (Netherlands)

^k LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^l ACADEMIC MEDICAL CENTER   (Netherlands)

^m REINIER DE GRAAF HOSPITAL   (Netherlands)

ⁿ MEANDER MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BUDESONIDE; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DRUG COST; FEMALE; FOLLOW UP; HEALTH CARE COST; HUMAN; INFLAMMATORY BOWEL DISEASE; INTERNET; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRODUCTIVITY; PROSPECTIVE STUDY; QUESTIONNAIRE; ULCERATIVE COLITIS; ANTAGONISTS AND INHIBITORS; ECONOMICS; HEALTH CARE DELIVERY; INFLAMMATORY BOWEL DISEASES; MIDDLE AGED; STATISTICAL MODEL;

DELIVERY OF HEALTH CARE; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HUMANS; INFLAMMATORY BOWEL DISEASES; LOGISTIC MODELS; MALE; MIDDLE AGED; SURVEYS AND QUESTIONNAIRES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84964576037     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0142481     Document Type: Article

References (26)

1. Van Der Valk ME, Mangen MJ, Leenders M, Dijkstra G, Van Bodegraven AA, Fidder HH, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNF alpha therapy: results from the COIN study. Gut 2014;63:72-9. doi: 10.1136/gutjnl-2012-303376 PMID: 23135759
2. Stark R, Konig HH, Leidl R. Costs of inflammatory bowel disease in Germany. Pharmacoeconomics 2006;24:797-814. PMID: 16898849
3. Odes S, Vardi H, Friger M, Russel MG, Munkholm P, Politi P, et al. Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. Gastroenterology 2006;131:719-728. PMID: 16952541
4. Kappelman MD, Rifas-Shiman SL, Porter CQ, Ollendorf DA, Sandler RS, Galanko JA, et al. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology 2008;135:1907-1913. doi: 10.1053/j.gastro.2008.09.012 PMID: 18854185
5. Juan J, Estiarte R, Colomé E, Artés M, Jiménez FJ, Alonso J. Burden of illness of Crohn's disease in Spain. Dig Liver Dis 2003;35:853-861. PMID: 14703880
6. Gibson TB, Ng E, Ozminkowski RJ, Wang S, Buurton WN, Goetzel RZ, et al. The direct and indirect cost burden of Crohn's disease and ulcerative colitis. J Occup Environ Med 2008;50:1261-1272. doi: 10.1097/JOM.0b013e318181b8ca PMID: 19001952
7. Blomqvist P, Ekbom A. Inflammatory bowel diseases: health care and costs in Sweden in 1994. Scand J Gastroenterol 1997;32:1134-1139. PMID: 9399395
8. Bassi A, Dodd S, Williamson P, Bodger K. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut 2004;53:1471-1478. PMID: 15361497
9. Bodger K. Cost of illness of Crohn's disease. Pharmacoeconomics 2002;20:639-652. PMID: 12162753
10. Mesterton J, Jönsson L, Almer SH, Befrits R, Friis-Liby I, Lindgren S. Resource use and societal costs for Crohn's disease in Sweden. Inflamm Bowel Dis 2009;15:1882-1890. doi: 10.1002/ibd.20939 PMID: 19408336
11. Prenzler A, Bokemeyer B, Von Der Schulenburg JM, Mittendorf T. Health care costs and their predictors of inflammatory bowel diseases in Germany. Eur J Health Econ 2011;12:273-283. doi: 10.1007/s10198-010-0281-z PMID: 20967482
12. Drummond M, Manca A, Sculpher M. Increasing the generalizability of economic evaluations: recommendations for the design, analysis, and reporting of studies. Int J Technol Assess Health Care 2005;21:165-171. PMID: 15921055
13. Burisch J, Vardi H, Pedersen N, et al. Costs and resource utilization for diagnosis and treatment during the initial year in a European inflammatory bowel disease inception cohort: an ECCO-EpiCom Study. Inflamm Bowel Dis 2015;21:121-131. doi: 10.1097/MIB.0000000000000250 PMID: 25437816
14. Kalkan A, Hallert E, Bernfort L, Husberg M, Carlsson P. Costs of rheumatoid arthritis during the period 1990-2010: a register-based cost-of-illness study in Sweden. Rheumatology 2014;53:153-160. doi: 10.1093/rheumatology/ket290 PMID: 24136064
15. Huscher D, Mittendorf T, Von Hinüber U, Kötter I, Hoese G, Pfäfflin A, et al. Evolution of cost structures in rheumatoid arthritis over the past decade. Ann Rheum Dis 2015;74:738-745. doi: 10.1136/annrheumdis-2013-204311 PMID: 24406543
16. Bernstein CN, Loftus EV, Jr., Ng SC, Lakatos PL, Moum B. Hospitalisations and surgery in Crohn's disease. Gut 2012;61:622-629. doi: 10.1136/gutjnl-2011-301397 PMID: 22267595
17. Targownik LE, Singh H, Nugent Z, Bernstein CN, et al. The Epidemiology of Colectomy in Ulcerative Colitis: Results From a Population-Based Cohort. Am J Gastroenterol 2012;107:1228-1235. doi: 10. 1038/ajg.2012.127 PMID: 22613902
18. Loly C, Belaiche J, Louis E. Predictors of severe Crohn's disease. Scand J Gastroenterol 2008;43:948-954. PMID: 19086165
19. Kappelman MD, Rifas-Shiman SL, Porter CQ, Ollendorf DA, Sandler RS, Galanko JA, et al. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology 2008;135:1907-13. doi: 10.1053/j.gastro.2008.09.012 PMID: 18854185
20. Solberg IC, Vatn MH, Hoie O, Stray N, Sauar J, Jahnsen J, et al. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol 2007;5:1430-1438. PMID: 18054751
21. Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Predictors of Crohn's disease. Gastroenterology 2006;130:650-656. PMID: 16530505
22. Hoie O, Wolters F, Riis L, Aamodt G, Solberg C, Bernklev T, et al. Ulcerative colitis: patient characteristics may predict 10-yr disease recurrence in a European-wide population-based cohort Am J Gastroenterol. 2007;102:1692-1701. PMID: 17555460
23. Moum B, Ekbom A, Vatn MH, Aadland E, Sauar J, Lygren I, et al. Clinical course during the 1st year after diagnosis in ulcerative colitis and Crohn's disease. Results of a large, prospective populationbased study in southeastern Norway, 1990-93. Scand J Gastroenterol 1997;32:1005-1012. PMID: 9361173
24. Bitton A, Peppercorn MA, Antonioli DA, Niles JL, Shah S, Bousvaros A, et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 2001;120:13-20. PMID: 11208709
25. Etchevers MJ, Aceituno M, Garcia-Bosch O, Ordás I, Sans M, Ricart E, et al. Risk factors and characteristics of extent progression in ulcerative colitis. Inflamm Bowel Dis 2009;15:1320-1325. doi: 10. 1002/ibd.20897 PMID: 19235909
26. Van Der Have M, Mangen MJ, Van Der Valk ME, Smeets HM, Van Bodegraven AA, Dijkstra G, et al. Effect of aging on healthcare costs of inflammatory bowel disease: a glimpse into the future. Inflamm Bowel Dis 2014;20:637-645. doi: 10.1097/01. MIB.0000442677.55051.03 PMID: 24518606